Apolipoprotein A-I and serum amyloid A plasma levels are biomarkers of acute painful episodes in patients with sickle cell disease

Abstract

BackgroundAcute painful episodes are the clinical hallmark of sickle cell disease and have been linked to morbidity and mortality in the sickle cell population. Design and MethodsWe undertook exploratory proteomic studies on paired plasma samples collected from a cohort of 26 adult sickle cell patients during steady state and on the first day of an acute painful episode. We screened for changes in abundance of specific protein peaks via surface-enhanced laser desorption/ionization time of flight mass spectrometry (SELDI-TOF MS), and confirmed the identify of candidate protein peaks by specific immunoassays. ResultsThe levels of hemoglobin, hematocrit, total protein, and albumin were lower and the levels of lactate dehydrogenase and absolute reticulocytes higher during acute painful episodes than during the steady state. Surface-enhanced laser desorption/ionization time of flight mass spectrometry spectral analysis consistently showed a mass-to-charge peak at 11.7 kDa with elevated intensities during acute painful episodes, which correlated significantly with the serum amyloid A immunoassay. Serum amyloid A levels were significantly elevated during acute painful episodes, especially in four patients with marked end-organ complications of such episodes. A second, recurring peak, less abundant during acute painful episodes, was present at 28.1 kDa; this peak was correlated significantly with immunoassay measurements of apolipoprotein A1. ConclusionsOn the average, plasma serum amyloid A rises and apolipoprotein AI falls during acute painful episodes. The serum amyloid A/apolipoprotein AI ratio increased in 81% of the patients during acute painful episodes, potentially making it a useful objective marker of such episodes. We propose that these protein alterations, known to contribute to endothelial dysfunction in other settings, might do likewise acutely in acute painful episodes and present a new target for therapeutic intervention in sickle cell disease. (ClincalTrials.gov Identifier: NCT00081523). 2010;95(9):1467-1472. doi:10.3324/haematol.2009 This is an open-access paper.Apolipoprotein A-I and serum amyloid A plasma levels are biomarkers of acute painful episodes in patients with sickle cell disease

Featured Article: Alterations of lecithin cholesterol acyltransferase activity and apolipoprotein A-I functionality in human sickle blood

“…In support of our findings suggesting remodeling of anti-to pro-inflammatory HDL in sickle plasma, the decreased ApoA-I and the increased SAA levels in plasma have been defined as novel biomarkers of acute painful episodes in SCD. 13 HDLs from sickle plasma were more sensitive to Cu 2þ -induced oxidation than HDL from normal. 71 An altered apolipoprotein profile was identified by mass spectrometry analysis in sickle patients with pulmonary hypertension.…”

High-density lipoprotein modulates thrombosis by preventing von Willebrand factor self-association and subsequent platelet adhesion

“…Consistent with this notion, clinical remission of TTP after plasma exchange has been observed in the face of persistent ADAMTS13 deficiency and elevated titers of inhibitory antibodies. 36 In addition to high total active VWF, low HDL and ApoA-I levels have also been described in sepsis, 37 malaria, 38 and sickle cell disease, 39,40 suggesting that higher ApoA-I concentrations may be protective of microvascular occlusion. Consistent with this suggestion, increased mortality associated with polymicrobial sepsis was observed in ApoA-Ideficient mice.…”

Featured Article: Depletion of HDL3high density lipoprotein and altered functionality of HDL2in blood from sickle cell patients

“…Defects of the cholesterol esterification process in SCD blood are reflected in the difference of both the concentration and activity of several plasma proteins related to this process. Both levels of LCAT 16,17 and ApoA-I, [18][19][20] which stimulates LCAT activity, are lower in SCD plasma. This decreased abundance is also observed for the PC transfer protein (PCTP), 21 which can provide PC to the LCAT reaction.…”

“…Serum amyloid A, which can inhibit activity of LCAT, 22 and the acute phase enzyme secretory phospholipase A 2 (sPLA 2 ), which can mobilize CE from lipoproteins, 23,24 are reported to be increased. 19,25 In addition to lower levels, the activities of LCAT, ApoAI, and of the RBC lysophospholipid re-acylating enzymes are altered. 17 The ability of HDL particles to exchange ApoA-I was impaired in SCD plasma and this worsened during Through its de-acylating action, sPLA 2 generates bioactive lysophospholipids, which are implicated in acute and chronic inflammation.…”